People: Halozyme Therapeutics, Inc. (HALO.O)

HALO.O on Consolidated Issue listed on NASDAQ Global Market

5.45USD
9:41am EST
Price Change (% chg)

$-0.04 (-0.73%)
Prev Close
$5.49
Open
$5.45
Day's High
$5.56
Day's Low
$5.44
Volume
8,059
Avg. Vol
344,500
52-wk High
$8.09
52-wk Low
$3.93

view people for:

Summary

Name Age Since Current Position
Kelley, Kenneth 50 2005 Chairman of the Board
Lim, Jonathan 37 2003 President, Chief Executive Officer, Director
Gustafson, Kurt 2009 Chief Financial Officer, Vice President - Finance
Fallon, William 52 2006 Vice President - Manufacturing & Operations
Frost, Gregory 37 Vice President, Chief Scientific Officer, Director
Ramsay, David 44 2009 Vice President - Corporate Development
Little, Robert 59 2006 Vice President, Chief Commercial Officer
Shepard, H. Michael 2009 Vice President - Discovery Research
Leff, Jonathan 2009 Vice President, Chief Medical Officer
Patton, John 62 2000 Director
Engler, Robert 64 2004 Director
Matsui, Connie 55 2006 Director
Kirk, Randal 55 2007 Director
Falberg, Kathryn 49 2007 Director
» Insider Trading

Biographies

Name Description
Kelley, Kenneth Mr. Kelley is Chairman of the Board of Directors of Halozyme Therapeutics, Inc. He brings over 25 years of entrepreneurial, venture capital, operational and technical biotechnology experience to Halozyme. Mr. Kelley has been the managing director of K2 Bioventures, a biomedical startup consulting company, since July 2004. Mr. Kelley currently serves as the Chief Executive Officer and Chair of the Board of Directors of privately held PaxVax, Inc. From April 2002 through June 2004, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and over eight years served as CEO, Director and Chair of the Board of Directors. Earlier, Mr. Kelley was an Associate at Institutional Venture Partners (IVP), where he participated in the financing of twenty biotech and medical companies, fifteen of which became public companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University. Mr. Kelley is the Chair of the Board of Directors and he also serves on the Audit Committee and the Compensation Committee.
Lim, Jonathan Dr. Jonathan E. Lim is President, Chief Executive Officer and Director of Halozyme Therapeutics, Inc. Dr. Lim joined Halozyme in 2003 and has served as Halozyme’s President and Chief Executive Officer since that time. From 2001 to 2003, Dr. Lim was a management consultant at McKinsey & Company, where he specialized in the health care industry, serving a wide range of start-ups to Fortune 500 companies in the biopharmaceutical, medical products, and payor/provider segments. From 1999 to 2001, Dr. Lim was a recipient of a National Institutes of Health Postdoctoral Fellowship, during which time he conducted clinical outcomes research at Harvard Medical School. He has published articles in peer-reviewed medical journals such as the Annals of Surgery and the Journal of Refractive Surgery. Dr. Lim’s prior experience also includes two years of clinical training in general surgery at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center; Founder and President of a health care technology start-up company; Founding Editor-in-Chief of the McGill Journal of Medicine; and basic science and clinical research at the Salk Institute for Biological Studies and Massachusetts Eye and Ear Infirmary. Dr. Lim is currently a California-licensed physician and is a volunteer surgeon in his spare time. He was a member of the strategic planning committee of the American Medical Association from 2002 to 2005. He earned a B.S., with honors, and an M.S. in Molecular Biology from Stanford University, an M.D. from McGill University, and an M.P.H. in Health Care Management from Harvard University.
Gustafson, Kurt Mr. Kurt Gustafson is Chief Financial Officer, Vice President - Finance of Halozyme Therapeutics Inc. Mr. Gustafson brings to Halozyme's senior management team a unique combination of operational and managerial experience in financial planning and analysis, accounting, treasury, and international responsibility gained during his 18 years with Amgen. In his most recent position, as Vice President, Manufacturing Finance, Mr.Gustafson was responsible for financial planning and cost accounting for each of Amgen's worldwide manufacturing sites and the Cost Accounting Group. Some of his previous positions at Amgen include: Vice President, Finance and CFO of Amgen Europe with responsibility for financial planning and accounting for European operations from 2004-2006, head of corporate financial planning and analysis from 2000-2004, and treasurer from 1998-2000. Before joining Amgen, he was with the accounting firm Laventhol & Horwath in Chicago. He received his BS in accounting from North Park University in Chicago and an MBA from UCLA.
Fallon, William Mr. William J. Fallon is Vice President - Manufacturing & Operations of Halozyme Therapeutics, Inc. Mr. Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. His responsibilities include oversight of all aspects of internal and external manufacturing and facilities operations, as well as bioprocess development. Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono’s approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in marine science and a B.A. in biology from Long Island University, and an M.S. in biology from Northeastern University.
Frost, Gregory Dr. Gregory I. Frost, Ph.D. is Vice President, Chief Scientific Officer and Director of Halozyme Therapeutics Inc. Dr. Frost co-founded Halozyme in 1999 and has spent more than fourteen years conducting research on the hyaluronidase family of enzymes. From 1998 to 1999, he was a Senior Research Scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work on developing the hyaluronidase technology. Prior to SKCC, his research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning and characterization of the human hyaluronidase gene family and the discovery of several metabolic disorders. He has authored multiple scientific peer-reviewed and invited articles in the hyaluronidase field and is an inventor on several key patents. Dr. Frost’s prior experience includes serving as a scientific consultant to a number of biopharmaceutical companies, including Q-Med AB, BioPhausia AB and Active Biotech AB. Dr. Frost is registered to practice before the U.S. Patent and Trademark Office and earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, and his Ph.D. in the Department of Pathology at the University of California, San Francisco, where he was an Achievement Rewards for College Scientists Scholar
Ramsay, David Mr. David A. Ramsay has been Vice President & Chief Financial Officer of Halozyme Therapeutics, Inc. Mr. Ramsay joined Halozyme in 2003 and has over 20 years of corporate financial experience spanning several industries. From 2000 to 2003, he was Vice President, Chief Financial Officer of Lathian Systems, a provider of technology-based sales solutions for the life sciences industry. Prior to Lathian, Mr. Ramsay was the Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company. Mr. Ramsay joined ICN in 1998 from ARCO, where he spent four years in various financial roles, most recently serving as Manager of Financial Planning & Analysis for the company’s 1,700-station West Coast Retail Marketing Network. Prior to ARCO, he served as Vice President, Controller for Security Pacific Asian Bank, a subsidiary of Security Pacific Corporation. He began his career as an Auditor at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay served on the Board of Directors for Axxora Life Sciences, Inc., a privately held, worldwide research reagent company which was recently sold to Enzo Biochem (NYSE:ENZ) of New York. He was also Chairman of the Audit Committee of Axxora. Mr. Ramsay graduated from the University of California, Berkeley, with a BS degree in Business Administration and earned his MBA degree with a dual major in Finance and Strategic Management from The Wharton School at the University of Pennsylvania. He become Vice President - Corporate Development of Halozyme Therapeutics Inc effective May 15, 2009.
Little, Robert Mr. Robert L. Little is Vice President, Chief Commercial Officer of Halozyme Therapeutics, Inc. Mr. Little joined Halozyme in 2006 with extensive experience in the pharmaceutical industry in general management, commercial operations, sales and marketing and business development. From 2003 to 2006, Mr. Little was Senior Vice President of Commercial Operations at Neurocrine Biosciences, where he was responsible for building and managing the sales and marketing functions. During his tenure, Mr. Little put in place a fully integrated commercial organization, including a marketing team, a 200-person CNS sales force and full logistical and infrastructure support in order to co-detail Zoloft® with Pfizer and in preparation for the introduction of Indiplon®. From 1985 to 2003, Mr. Little was at Pharmacia, Inc. where his most recent position was Group Vice President, Diversified Products. His responsibilities included managing Pharmacia’s Diversified Products business, as well as forming a new global business unit merging pricing, reimbursement and health outcomes groups to focus on current industry issues, pricing and drug values. From 1999 to 2001, Mr. Little was Group Vice President, Specialty Products and worldwide head of a $2.5 billion, global specialty products business (ophthalmology, endocrinology, neurology and others). Mr. Little previously held a number of positions within Pharmacia, including President and Managing Director of Pharmacia in Milan, Italy, President of Pharmacia & UpJohn in Canada and President of Pharmacia, Inc. in Canada. Prior to joining Pharmacia, he held positions at Adria Laboratories and Miles Laboratories/Bayer AG in the U.K., Italy, and the U.S. Mr. Little earned his degree in economics and finance from the West London Business School, Ealing Technical College.
Shepard, H. Michael Dr. Michael Shepard, Ph.D., is Vice President - Discovery Research of Halozyme Therapeutics, Inc. Dr. Shepard brings over 25 years of experience in the biotechnology industry to Halozyme. At Genentech, Dr. Shepard led the team that discovered the breast cancer drug, Herceptin (trastuzumab), which was designed to attack HER2 positive breast cancers by inhibiting their growth and enhancing their sensitivity to the immune system. In 2007.In addition to his accomplishments at Genentech, Dr. Shepard built successful programs at various biotechnology companies in areas as diverse as antibiotics, cancer gene therapy and receptor fusion proteins serving as chief scientific officer of Canji, Inc. and, most recently, founder and president of Receptor BioLogix, Inc. Dr. Shepard received his bachelor's degree in zoology from UC Davis and his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University, where he was a Damon Runyon Cancer Research Foundation Fellow.
Leff, Jonathan Dr. Jonathan Leff, M.D., is Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. While at Roche, Dr. Leff managed the worldwide clinical and registration phase of development for MabThera(TM)/Rituxan(TM), ocrelizumab, and Actemra(TM). From 2002 to 2007, Dr. Leff was at Amgen Inc., where he was vice president, North American medical affairs. His responsibilities included leadership of a department of 500 professionals, and the oversight of 5 therapeutic areas, 8 marketed products, and 4 late stage pipeline products, which involved the support and growth of 5 blockbuster brands: Neupogen(TM), Neulasta(TM), Epogen(TM), Aranesp(TM), and Enbrel(TM). In his prior role at Amgen as senior medical director and department head of osteoporosis research, he was responsible for the Phase 2 and 3 osteoporosis clinical trials for denosumab in over 10,000 patients, including a 7,800 patient fracture study. From 1994 to 2002, Dr. Leff was at Merck & Co., where he performed Phase 1 through Phase 4 clinical research studies for Singulair(TM), a treatment for asthma, which resulted in a global filing and regulatory approval. Earlier in his career, Dr. Leff was a faculty member in the Pulmonary Division of the University of Colorado School of Medicine, with responsibilities for patient care, teaching and basic research. Dr. Leff is board certified in internal medicine, pulmonary medicine, and critical care medicine. He received his Bachelor of Arts in chemistry and M.D. from the University of Pennsylvania.
Patton, John John S. Patton, Ph.D., is a Director of Halozyme Therapeutics, Inc. since 2000. He is currently the founder and President of Dance Pharmaceuticals. Prior to Dance Pharmaceuticals, Dr. Patton co-founded Nektar Therapeutics (Nasdaq-NKTR) (formerly Inhale Therapeutic Systems) and he served as Chief Scientific Officer from November 2001, and as a director from 1990, through 2008. He is an expert in the delivery of peptides and proteins. Before co-founding Nektar Therapeutics, Dr. Patton led the drug delivery group at Genentech, Inc., where he demonstrated the feasibility of systemic delivery of large molecules through the lungs. Prior to joining Genentech, Inc., he was a tenured professor at the University of Georgia. He has published a wide range of articles and has presented his work in national and international arenas. Dr. Patton received his Ph.D. in Biology from the University of California, San Diego, and held post-doctoral positions in biomedicine at Harvard Medical School and the University of Lund in Sweden. Dr. Patton chairs Companys' Scientific and Clinical Advisory Board.
Engler, Robert Dr. Engler is a Director of Halozyme Therapeutics, Inc. since 2004. He spent his career as a Cardiologist at the Veterans Affairs Medical Center and the University of California, San Diego, where he retired as Professor Emeritus in 2001. While at the Veterans Affairs Medical Center, Dr. Engler served as Associate Chief of Staff and Chief of Research and was an attending physician, in addition to running an active cardiovascular research laboratory. His research and clinical work led to the founding of two successful biotechnology companies: Gensia, Inc., and Collateral Therapeutics, Inc. He also founded and served as President of the Veterans Medical Research Foundation. Dr. Engler graduated from Georgetown Medical School. Dr. Engler is the Chair of the Nominating and Governance Committee.
Matsui, Connie Ms. Matsui is a Director of Halozyme Therapeutics, Inc. since 2006. She has over 16 years of general management experience in the biotechnology industry. Prior to her retirement in January 2009, she was the Executive Vice President, Knowledge and Innovation Networks for Biogen Idec, Inc. She served in several positions since joining IDEC Pharmaceuticals in November 1992, including Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University.
Kirk, Randal Mr. Kirk is a Director of Halozyme Therapeutics, Inc. since 2007. He has served as the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk, since March 1999. Additionally, Mr. Kirk founded and became Chairman of the Board of Directors of New River Pharmaceuticals Inc. (previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, which was a specialty pharmaceutical company focused on developing novel pharmaceuticals and improved versions of widely-prescribed drugs, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Mr. Kirk co-founded General Injectables & Vaccines, Inc. (GIV), a pharmaceutical distributor, in 1983 and served as Chairman of the Board of Directors of GIV prior to the sale of that company in 1998. Previously, Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, and was a member of the board of directors of Howe and Rusling, Inc., a registered investment advisory firm, from 2001 through 2006. He served on the Virginia Bioinformatics Institute Policy Advisory Board from March 2004 through November 2007. Mr. Kirk has served on the Board of Visitors of Radford University since July 2003, was elected Rector of the Board in September 2006, and also has served on the board of directors of the Radford University Foundation, Inc. since September 1998. He was appointed to the Virginia Advisory Council on Revenue Estimates in July 2006, and was appointed as a member of the board of directors of the Virginia University Research Partnership in July 2007. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia. Mr. Kirk serves on the Compensation Committee and the Nominating and Governance Committee.
Falberg, Kathryn Ms. Falberg is a Director of Halozyme Therapeutics, Inc. since 2007. She joined ARCA biopharma, Inc. (Nasdaq: ABIO) in February 2009 as its Chief Financial Officer and Chief Operating Officer. From 2003 to 2008 Ms. Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm. From October 2001 to June 2002 Ms. Falberg was a consultant to Inamed, a medical device company, and briefly served as its interim Chief Financial Officer. Ms. Falberg joined Amgen Inc., a global biotechnology company, in 1995 as Treasurer, and advanced through a series of positions of increasing responsibility, culminating in her appointment as Senior Vice President, Finance and Strategy, and Chief Financial Officer in 1998. Ms. Falberg left Amgen Inc. in July 2001. Ms. Falberg has served on the board of directors for companies in multiple industries and she currently serves on the board of QLT, Inc. (Nasdaq:QLTI) and ESS Technology, a privately held semiconductor company. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles. Ms. Falberg is the Chair of the Audit Committee and she also serves on the Nominating and Governance Committee.

Basic Compensation

Name Fiscal Year Total
Kelley, Kenneth --
Lim, Jonathan 628,522
Gustafson, Kurt --
Fallon, William 354,308
Frost, Gregory 467,556
Ramsay, David 370,835
Little, Robert 429,265
Shepard, H. Michael --
Leff, Jonathan --
Patton, John --
Engler, Robert --
Matsui, Connie --
Kirk, Randal --
Falberg, Kathryn --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Kelley, Kenneth 0 0
Lim, Jonathan 2,648,213 4,328,252
Gustafson, Kurt 0 0
Fallon, William 0 0
Frost, Gregory 1,887,256 5,181,134
Ramsay, David 511,695 806,379
Little, Robert 0 0
Shepard, H. Michael 0 0
Leff, Jonathan 0 0
Patton, John 0 0
Engler, Robert 0 0
Matsui, Connie 0 0
Kirk, Randal 0 0
Falberg, Kathryn 0 0

Insider Trading

» Full list on Insider Trading
view people for: